Publications:

Engineering Multidimensional Evolutionary Forces to Combat Cancer.

Cancer Discovery

McCoach, Caroline E CE; Bivona, Trever G TG

Publication Date: 2019-05

Variant appearance in text: PI3K: N212D

PubMed Link: 30992280

Variant Present in the following documents:

• Main text

View BVdb publication page

AXL receptor tyrosine kinase as a therapeutic target in NSCLC.

Lung Cancer (Auckland, N.Z.)

Okimoto, Ross A RA; Bivona, Trever G TG

Publication Date: 2015

Variant appearance in text: PI3K: N212D

PubMed Link: 28210148

Variant Present in the following documents:

• Main text
• lctt-6-027.pdf

View BVdb publication page

Secrets of drug resistance in NSCLC exposed by new molecular definition of EMT.

Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research

Neel, Dana S DS; Bivona, Trever G TG

Publication Date: 2013-01-01

Variant appearance in text: PI3K: N212D

PubMed Link: 23172883

Variant Present in the following documents:

• Main text

View BVdb publication page

Resiliency of lung cancers to EGFR inhibitor treatment unveiled, offering opportunities to divide and conquer EGFR inhibitor resistance.

Cancer Discovery

Blakely, Collin M CM; Bivona, Trever G TG

Publication Date: 2012-10

Variant appearance in text: PIK3CA: N212D

PubMed Link: 23071030

Variant Present in the following documents:

• Main text

View BVdb publication page